Treatment with immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1), is becoming a novel therapeutic paradigm for melanomas (1). This evidence concerns the gene CD274 and melanoma.